As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Aims to boost speed & precision in patient care
Three-day programme focuses on advanced socket design, myoelectric technology and clinical skill development
C. P. Radhakrishnan urged graduates to uphold ethical standards and maintain a commitment to patient care
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Targets high-growth eye care expansion push
Subscribe To Our Newsletter & Stay Updated
